

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



December 25, 2024

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-957-3090

**Notice concerning Memorandum of Understanding
to enter into Master Transaction Agreement
between TAUNS Laboratories, Inc. and Roche Diagnostics K.K.**

TAUNS Laboratories, Inc. (President and CEO: Masaki Nonaka, hereinafter “TAUNS”) and Roche Diagnostics K.K. (President and CEO: Makoto Ogasawara, hereinafter “Roche”) have signed a Memorandum of Understanding to enter into a Master Transaction Agreement. This agreement will define the basic terms and conditions, rights, and obligations of both companies with respect to the sale of TAUNS' products to Roche. The purpose of this agreement is to further develop the business of both companies.

The companies will continue to discuss and review the details of the definitive agreement. The details set forth below are as contemplated at the time of the signing of the Memorandum of Understanding and are subject to change as a result of the companies' discussions and review of the definitive agreement. When a definitive agreement is signed, we will make an announcement in a timely manner.

1. Details of the products to be sold by TAUNS to Roche
 - (1) ImunoAce SARS-CoV-2 III (Sales Standard: 10 tests)
 - (2) ImunoAce SARS-CoV-2/Flu (Sales Standard: 10 tests)

2. Overview of the two companies

(1) TAUNS

①	Name	TAUNS Laboratories, Inc.
②	Location	761-1 Kamishima, Izunokuni-shi, Shizuoka 410-2325, Japan
③	Name and title of representative	Masaki Nonaka, President and CEO
④	Business description	Development, manufacture, sales and export/import of in vitro diagnostics and research reagents Manufacture, sales and export/import of intermediates of the above products

(2) Roche

①	Name	Roche Diagnostics K.K.
②	Location	Konan, Minato-ku 1 Chome 2-70 108-0075 Tokyo Japan Japan
③	Name and title of representative	Makoto Ogasawara, President and CEO
④	Business description	Import, manufacture and sale of in vitro diagnostics, equipment, research reagents and equipment, and diagnostic and pharmaceutical raw materials

(3) Relationship between the two companies

There are no capital relationships between TAUNS and Roche to be noted specifically.

There are no personnel relationships between TAUNS and Roche to be noted specifically.

There are no business relationships between TAUNS and Roche to be noted specifically.

There are no related party relationships between TAUNS and Roche to be noted specifically.

3. Schedule

(1) Conclusion of the Memorandum of Understanding: December 25, 2024

(2) Conclusion of the Master Transaction Agreement: January 2025 (estimated)

(3) Commencement of sales from TAUNS to Roche: January 2025 (estimated)

4. Outlook

At present, we believe that this alliance will have a minimal impact on the business performance of TAUNS, but we will disclose any significant impact as soon as it is identified.